Actuate Therapeutics receives Nasdaq notice over minimum bid price deficiency

• Actuate Therapeutics received a Nasdaq notice on October 28, 2026, for closing below the $1 minimum bid price for 30 consecutive business days.
• Compliance requires a closing bid price of at least $1 for 10 consecutive business days by April 26, 2027, alongside other listing requirements.
• The notice has no immediate listing impact; common stock continues trading on the Nasdaq Global Market under ACTU.
• A conditional 180-day extension may be available through a Nasdaq Capital Market transfer; failure to regain compliance risks delisting.
• A separate July 15, 2026, notice set January 11, 2027, as the deadline to meet minimum market value of listed securities requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008193), on October 30, 2026, and is solely responsible for the information contained therein.